Wegovy 6-Month Weight Loss: What the Evidence Actually Shows

What the STEP 1 trial tells us about the six-month mark

The STEP 1 trial is the best source we have for understanding how semaglutide works over time. Participants started at 0.25mg and stepped up roughly every four weeks, so by week 20 (around five months) most had only recently reached the 1.7mg dose, one step below the 2.4mg maintenance level. That matters, because the appetite-suppressing effect of semaglutide strengthens with each dose increase.

Looking at the trial's published weight-loss curves, average loss at week 24 (six months) sat in the 8–12% range for people on the active treatment. That is already clinically significant, enough to meaningfully reduce blood pressure and improve cholesterol in many people. But the curves keep falling for another 12–18 months after that, which is why the 68-week average of roughly 15% is so much higher. Six months, in other words, is not when Wegovy has finished working.

For a closer look at how results build in the earlier weeks, our month-by-month breakdown of Wegovy weight loss follows the data through each stage of the titration schedule.

One practical habit worth building early: a short note in your phone each week, just the date and your weight. Tracking trends rather than daily fluctuations takes the frustration out of normal variation and gives your prescriber something concrete to work with at review.

Why your personal six-month result may differ from the trial average

Trial averages are useful anchors, but they obscure a wide spread of individual responses. In STEP 1, some participants lost more than 20% by the end of the study; others lost less than 5%. Several factors shape where on that range you land.

Dose reached by month six is probably the biggest driver. If you've had to slow your titration because of nausea or other gastrointestinal side effects (which are common in the early weeks and usually settle) you may still be on 1.0mg or 1.7mg at the six-month mark. That is not a failure; it is the dose schedule working as intended, prioritising tolerability. Your weight loss will continue as the dose increases.

Starting weight also matters arithmetically: a 15% reduction looks very different on someone starting at 120 kg versus 90 kg, even though the percentage is identical. Diet quality and activity levels alongside treatment play a role too, and if you want to understand what is realistic early on, our guide to Wegovy weight loss at one month sets honest expectations for that first stage. Semaglutide reduces appetite significantly, but the NHS guidance on semaglutide is clear that the medicine works alongside a reduced-calorie diet and increased physical activity, not instead of them.

If you're weighing up Wegovy against other options, our full Wegovy overview covers the mechanism, eligibility and what to expect in more detail.

The 7.2mg dose and what it means for longer-term expectations

Until April 2026, 2.4mg was the highest maintenance dose available for Wegovy in the UK. The MHRA's approval of a dedicated single-dose 7.2mg pen on 14 April 2026 changed that picture considerably. Trial data for the higher dose reported average weight loss of around 20.7% over 72 weeks, closer to what tirzepatide (Mounjaro) has shown in its own trials and well above the 2.4mg average.

What this means practically is that people starting Wegovy now may reach a higher eventual maintenance dose than those who started a year ago, and six-month results may come to look different as protocols evolve. The titration still begins at 0.25mg regardless of which maintenance dose you are aiming for. Specific dose availability is always confirmed at your consultation, not before, prescribers make that decision based on your individual clinical picture.

For context on how costs vary as treatment changes, this page looks honestly at Wegovy pricing in the UK, including what a transparent private price should cover.

What happens if six months hasn't produced the change you expected

NICE's guidance on semaglutide, published as TA875, recommends reviewing continuation if less than 5% weight loss is seen after six months on the maintenance dose. That threshold matters: it is the maintenance dose specifically, not whatever dose you happen to be on at the six-month mark. Many people are still titrating at that point and would not yet meet that review trigger.

If you have reached maintenance and the response has been modest, that is a conversation to have openly with your prescriber, not a reason to stop before exploring what is driving it. Factors like medication interactions, thyroid conditions or other health variables can all affect response and deserve proper clinical review. To understand how weight loss typically builds across a ninety-day period before that point, our overview of Wegovy weight loss at three months gives a useful mid-way reference. For those wanting to revisit the very beginning of treatment, our look at one month on Wegovy walks through what the first weeks of the programme typically involve.

Our prescribers review every patient before each repeat order, so there is a built-in checkpoint at every stage of treatment. If you have questions before you start, our FAQs cover many of the most common ones, and the team is available seven days a week via the contact page. When you're ready to understand your own eligibility, checking your eligibility with a free consultation is the right next step.